Shanmuga Hospital Appoints Dr. Mehak Jamwal as AVP

Shanmuga Hospital Limited announces appointment of Dr. Mehak Jamwal as Assistant Vice President - Operations effective March 16, 2026, bringing 10 years healthcare experience.

Shanmuga Hospital Commissions Litho Evo Laser Machine

Shanmuga Hospital Limited has purchased and commissioned a Litho Evo Laser Machine at its hospital facility to enhance medical infrastructure and strengthen advanced treatment capabilities in urology and minimally invasive procedures.

Shanmuga Hospital Limited Reports Full Utilization of IPO Proceeds Worth Rs 2,061.72 Lakhs

Shanmuga Hospital Limited filed a statement confirming no deviations in the utilization of IPO proceeds during the half year ended September 30, 2025. The company raised Rs 2,061.72 lakhs through its IPO with allotment date of February 18, 2025. The opening unutilized IPO proceeds of Rs 1,115.50 lakhs as of March 31, 2025 were fully utilized during May 2025 for the purchase and installation of a robotic surgical machine under capital expenditure. The total IPO funds were allocated across capital expenditure (Rs 1,452.50 lakhs), issue expenses (Rs 225.94 lakhs), and general corporate purposes (Rs 383.28 lakhs). The statement was reviewed by the Audit Committee and approved by the Board on November 12, 2025. External auditors PPN and Company certified that there were no deviations in the use of public issue proceeds for the reporting period.

Shanmuga Hospital Reports 201.13 Lakh Net Profit for Half-Year Ended September 2025

Shanmuga Hospital Limited announced its unaudited financial results for the half-year ended September 30, 2025. The company reported a net profit of ₹201.13 lakhs compared to ₹181.38 lakhs in the previous period and ₹239.29 lakhs in the corresponding period last year. Revenue from operations stood at ₹2,462.07 lakhs. Total expenses were ₹2,201.68 lakhs, with cost of consumption being the largest component at ₹813.05 lakhs, followed by other expenses at ₹828.12 lakhs and employee benefits expense at ₹366.76 lakhs. The company's earnings per share was ₹1.48 for both basic and diluted calculations. The company completed full utilization of its IPO proceeds of ₹2,061.72 lakhs during the reporting period, with ₹1,452.50 lakhs allocated to capital expenditure and ₹383.28 lakhs for general corporate purposes. The Board of Directors approved these results at their meeting held on November 12, 2025.